Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
Holding RXST?
Track your performance easily
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.29 - $66.54
Previous CloseN/A
Volume110.15K
Average Volume (3M)807.11K
Market Cap
$1.35B
Enterprise Value$1.74B
Total Cash (Recent Filing)$80.67M
Total Debt (Recent Filing)$4.53M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 11, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding40,304,466
10 Day Avg. Volume748,109
30 Day Avg. Volume807,105
Standard Deviation0.16
R-Squared0.14
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.50
Price to Cash Flow (P/CF)518.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue13.57
Enterprise Value/Gross Profit32.38
Enterprise Value/Ebitda-103.28
Forecast
1Y Price Target
$56.63Price Target Upside84.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
RxSight News
PremiumCompany Announcements
RxSight, Inc. Reports Strong Q3 Financial ResultsBulls Say, Bears Say
Bulls Say
Financial PerformanceRXST's 2025 revenue guidance of $185-197m (+32-41%) was 2% higher than the Street ($188m) at the midpoint, indicating confidence in future growth.
Growth And Market PositionRXST remains one of the most compelling growth stories in medtech as it is part of a small group of companies expected to grow revenue 30+% in 2025.
Product Demand And Market ExpansionRXST sold more Light Adjustable Lenses than expected, indicating strong demand for its products and suggesting a strong competitive position in the premium IOL market.
Bears Say
Competition And Market DynamicsThe risk from US premium IOL competition may be more significant than investors realize, with JNJ’s new Tecnis Odyssey lens having a notable impact.
Financial Performance And Investor SentimentWith now two quarters in a row of mixed results, these results could feed into fears that RxSight may be hitting a wall.
Sales Forecast And Market ExpectationsThe sales estimate for 2024 was slightly lowered, and the price target decreased, reflecting recent multiple contraction in the market.
---
Ownership Overview
4.88% Insiders
19.87% Mutual Funds
0.30% Other Institutional Investors
60.14% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $26.29 and its highest was $66.54 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $1.35B.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Mar 11, 2025 which is in 56 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Nov 07, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.086.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.17.
How many shares outstanding does RxSight have?
RxSight has 40,304,466 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -5.585%.
Which hedge fund is a major shareholder of RxSight?
Among the largest hedge funds holding RxSight’s share is RA Capital Management. It holds RxSight’s shares valued at 194M.
---
RxSight Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.63 (84.34% Upside)
$56.63 (84.34% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 85%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 17.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.75%
12-Months-Change
Fundamentals
Return on Equity
-13.99%
Trailing 12-Months
Asset Growth
70.73%
Trailing 12-Months
Company Description
RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
---
RXST Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive trajectory for RxSight with strong revenue and sales growth, particularly in LAL and LDD units. The company has improved gross margins and revised its revenue guidance upwards. However, these positive developments are tempered by a net loss for the quarter and increased operating expenses. Additionally, external factors like hurricanes have had some impact on operations.Read More>---
RXST Stock 12 Month Forecast
Average Price Target
$56.63
▲(84.34% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Akero Therapeutics
―
ALX Oncology Holdings
―
Kiniksa Pharmaceuticals
―
RAPT Therapeutics
―
Synlogic
―
Best Analysts Covering RXST
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+68.20%
reiterated a buy rating 2 days ago
Copying David Saxon's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +68.20% per trade.
---